Median follow-up time was 44.0 months. The survival rate at 48 months was 65.1% for ERLEADA  + ADT patients vs 51.8% for placebo + ADT patients. OS improved regardless of Gleason score, age, high- or low-disease volume, and metastasis stage at diagnosis.